# Clinical Trials Data EGFR - Document 58

# CPCT-05 Biopsy Protocol Patient Selection

## Clinical Trial: https://clinicaltrials.gov/study/NCT01904916

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Locally advanced (incurable) or metastatic cancer from a histological or cytological proven solid tumor\n\* Indication for systemic treatment with anti-cancer agents (with no treatment options with curative intent)\n\* Measurable locally advanced (incurable) or metastatic lesion(s), according to RECIST 1.1 criteria.\n\* Safe biopsy of a metastatic or locally advanced lesion possible\n\* No contraindications for lidocaine (or its derivatives) and/or midazolam and/or phentanyl\n\* Adequate organ function\n\* WHO performance status 0-2\n\* Age \\> 18 yr\n\* Expected adequacy to follow up\n\* Written informed consent\n\nExclusion Criteria:\n\n\u2022 If one or more of the above mentioned inclusion criteria is not met",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
The provided information doesn't exclude patients with EGFR mutations. A patient with an EGFR mutation \*could\* be eligible if they also meet \*all\* of the other inclusion criteria (e.g., having advanced or metastatic solid tumor with an indication for systemic anti-cancer treatment, measurable lesion, etc.) and \*none\* of the exclusion criteria. Having an EGFR mutation itself is neither an inclusion nor an exclusion criterion as described. Therefore, more information about the specific patient's condition is needed to determine their eligibility.